文献速递慢性肾脏病血液净化与透析

磷酸盐平衡与慢性肾脏病-矿物质骨异常

Phosphate Balance and CKD-Mineral Bone Disease.
PubMed 文献 · Kidney Int Rep · 2021-05-17

慢性肾脏病-矿物质骨异常(CKD-MBD)以实验室异常、骨异常和血管钙化为特征,与心血管发病和死亡增加相关。血清磷酸盐异常是独立危险因素,磷酸盐潴留驱动CKD-MBD多种紊乱;现有管理策略不足,tenapanor通过抑制钠氢交换体3减少肠道旁细胞磷酸盐吸收。

要点

  • 血清磷酸盐异常是CKD患者心血管发病和死亡的独立危险因素。
  • 磷酸盐潴留驱动PTH和FGF23升高、低钙血症及低维生素D等紊乱。
  • 现有降磷策略(限磷饮食、透析、磷结合剂)在透析患者中难以持续达标。

核心结论

  • 有效控制磷酸盐是CKD-MBD的合理治疗靶点,但现有策略不足,需考虑肠道磷酸盐吸收新机制的新型疗法。

研究设计与样本

  • 综述性文章,未报告系统检索范围与样本量。

主要发现

  • 血清磷酸盐异常是CKD患者心血管发病和死亡的独立危险因素。
  • 磷酸盐潴留启动并驱动CKD-MBD多种紊乱,包括PTH和FGF23升高、低钙血症、低维生素D。
  • 磷结合剂减少肠道可吸收磷酸盐,但不影响主要的磷酸盐吸收途径。
  • tenapanor作为钠氢交换体3抑制剂,在多项临床试验中显示降低血清磷酸盐浓度。
  • tenapanor通过减少肠道旁细胞磷酸盐吸收途径发挥作用。

临床怎么用

  • CKD-MBD管理应重视磷酸盐控制,但需认识现有策略在透析患者中达标率有限。
  • tenapanor为降低血清磷酸盐提供新机制选择,适用于考虑肠道旁细胞吸收途径干预的患者。

局限性

  • 本文为综述,未提供原始研究数据或系统评价方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic kidney disease-mineral bone disorder (CKD-MBD) is a common comorbidity in patients with CKD. Characterized by laboratory abnormalities, bone abnormality, and vascular calcification, CKD-MBD encompasses a group of mineral and hormone disturbances that are strongly associated with increased cardiovascular (CV) morbidity and mortality. Abnormal serum phosphate concentrations are an independent risk factor for CV morbidity and mortality, and overall mortality. Phosphate retention plays a central role in initiating and driving many other disturbances in CKD-MBD (e.g., increased parathyroid hormone and fibroblast growth factor 23 concentrations, hypocalcemia, low vitamin D) that are also linked to increased CV risk. Thus, effective phosphate control is a logical therapeutic target for CKD-MBD treatment. Current phosphate management strategies (dietary restrictions, dialysis, phosphate binders) are insufficient to consistently achieve and maintain target phosphate concentrations in patients on dialysis. Phosphate binders reduce available phosphate for intestinal absorption but do not impair the dominant phosphate absorption pathway. Novel therapies that consider new mechanistic understandings of intestinal phosphate absorption are needed. One such therapy is tenapanor, a targeted sodium-hydrogen exchanger isoform 3 inhibitor that has been shown to reduce serum phosphate concentrations in multiple clinical trials. Tenapanor has a novel mechanism of action that reduces intestinal phosphate absorption in the primary paracellular phosphate absorption pathway.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Sprague SM, Martin KJ, Coyne DW, et al. Phosphate Balance and CKD-Mineral Bone Disease. Kidney Int Rep. 2021. PMID: 34386654. doi:10.1016/j.ekir.2021.05.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。